These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30869425)

  • 1. [Reactivation of tuberculosis during treatment with inhibitors of TNF].
    Miossec P
    Rev Prat; 2018 May; 68(5):537-540. PubMed ID: 30869425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor.
    Robert M; Miossec P
    Cell Mol Immunol; 2021 Jul; 18(7):1644-1651. PubMed ID: 34021269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of tuberculosis infection in anti-TNF-α biological therapy: from bench to bedside.
    Xie X; Li F; Chen JW; Wang J
    J Microbiol Immunol Infect; 2014 Aug; 47(4):268-74. PubMed ID: 23727394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberculosis screening prior to anti-tumor necrosis factor therapy among patients with immune-mediated inflammatory diseases in Japan: a longitudinal study using a large-scale health insurance claims database.
    Tomio J; Yamana H; Matsui H; Yamashita H; Yoshiyama T; Yasunaga H
    Int J Rheum Dis; 2017 Nov; 20(11):1674-1683. PubMed ID: 29076252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Kim JW; Shim JJ; Jang JY
    J Korean Med Sci; 2015 Feb; 30(2):173-9. PubMed ID: 25653489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change.
    Nogueira M; Warren RB; Torres T
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):824-834. PubMed ID: 32790003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF-α/IL-2 ratio discriminates latent from active tuberculosis in immunocompetent children: a pilot study.
    Gourgouillon N; de Lauzanne A; Cottart CH; Curis E; Debord C; Guérin-El Khourouj V; Pédron B; Faye A; Sterkers G
    Pediatr Res; 2012 Oct; 72(4):370-4. PubMed ID: 22797138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette Guérin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis.
    Olleros ML; Vesin D; Lambou AF; Janssens JP; Ryffel B; Rose S; Frémond C; Quesniaux VF; Szymkowski DE; Garcia I
    J Infect Dis; 2009 Apr; 199(7):1053-63. PubMed ID: 19222369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of latent tuberculosis infection in autoimmune disorders such as psoriasis and in chronic respiratory diseases, including lung cancer.
    Bordignon V; Bultrini S; Prignano G; Sperduti I; Piperno G; Bonifati C; Filippetti M; Toma L; Latini A; Di Cecio M; Giuliani A; Vocaturo A; Trento E; D' Agosto G; Francesconi F; Cataldo A; Vento A; Cilenti V; Berardesca E; Ameglio F; Cordiali Fei P; Ensoli F
    J Biol Regul Homeost Agents; 2011; 25(2):213-20. PubMed ID: 21880210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of tuberculosis in patients treated with TNF antagonists.
    Salgado E; Gómez-Reino JJ
    Expert Rev Clin Immunol; 2011 May; 7(3):329-40. PubMed ID: 21595599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
    Theis VS; Rhodes JM
    Aliment Pharmacol Ther; 2008 Jan; 27(1):19-30. PubMed ID: 17944997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States.
    Qumseya BJ; Ananthakrishnan AN; Skaros S; Bonner M; Issa M; Zadvornova Y; Naik A; Perera L; Binion DG
    Inflamm Bowel Dis; 2011 Jan; 17(1):77-83. PubMed ID: 20848501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment.
    Mir Viladrich I; Daudén Tello E; Solano-López G; López Longo FJ; Taxonera Samso C; Sánchez Martínez P; Martínez Lacasa X; García Gasalla M; Dorca Sargatal J; Arias-Guillén M; García García JM
    Arch Bronconeumol; 2016 Jan; 52(1):36-45. PubMed ID: 26187708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice.
    Cantini F; Nannini C; Niccoli L; Iannone F; Delogu G; Garlaschi G; Sanduzzi A; Matucci A; Prignano F; Conversano M; Goletti D;
    Autoimmun Rev; 2015 Jun; 14(6):503-9. PubMed ID: 25617816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study.
    Bermejo F; Algaba A; Chaparro M; Taxonera C; Garrido E; García-Arata I; Guerra I; Gisbert JP; Olivares D; de-la-Poza G; López-Sanromán A
    Dig Liver Dis; 2013 Sep; 45(9):733-7. PubMed ID: 23587496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does anti-TNF therapy influence the performance of mycobacterium tuberculosis antigen-specific interferon-gamma assays? A French multicenter experience.
    Del Tedesco E; Roblin X; Laharie D; Peyrin Biroulet L
    Inflamm Bowel Dis; 2011 Aug; 17(8):1824. PubMed ID: 21744437
    [No Abstract]   [Full Text] [Related]  

  • 17. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis Screening and Reactivation Among a National Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Antagonists.
    Hou JK; Kramer JR; Richardson P; Sansgiry S; El-Serag HB
    Inflamm Bowel Dis; 2017 Feb; 23(2):254-260. PubMed ID: 27997433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can ELISpot replace the tuberculin skin test for latent tuberculosis?
    Greveson K
    Br J Nurs; 2009 Nov 12-25; 18(20):1248-54. PubMed ID: 20081663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
    Baddley JW; Cantini F; Goletti D; Gómez-Reino JJ; Mylonakis E; San-Juan R; Fernández-Ruiz M; Torre-Cisneros J
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S10-S20. PubMed ID: 29459143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.